Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Mimedx (MDXG) over the last 15 years, with Q3 2024 value amounting to $217000.0.

  • Mimedx's Income towards Parent Company rose 17045.45% to $217000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $217000.0, marking a year-over-year decrease of 8959.23%. This contributed to the annual value of $421000.0 for FY2024, which is 10457.06% up from last year.
  • As of Q3 2024, Mimedx's Income towards Parent Company stood at $217000.0, which was up 17045.45% from $4000.0 recorded in Q2 2024.
  • Mimedx's 5-year Income towards Parent Company high stood at $9.8 million for Q4 2022, and its period low was -$19.4 million during Q3 2020.
  • Its 5-year average for Income towards Parent Company is -$4.8 million, with a median of -$3.0 million in 2023.
  • The largest annual percentage gain for Mimedx's Income towards Parent Company in the last 5 years was 483969.85% (2022), contrasted with its biggest fall of 51090.5% (2022).
  • Over the past 5 years, Mimedx's Income towards Parent Company (Quarter) stood at -$16.6 million in 2020, then skyrocketed by 101.2% to $199000.0 in 2021, then soared by 4839.7% to $9.8 million in 2022, then plummeted by 77.73% to $2.2 million in 2023, then crashed by 90.09% to $217000.0 in 2024.
  • Its Income towards Parent Company stands at $217000.0 for Q3 2024, versus $4000.0 for Q2 2024 and $200000.0 for Q1 2024.